Adult Dosing
Hemodialysis associated iron deficiency anemia
- 125 mg of elemental iron diluted in 100 mL of 0.9% NaCl IV infusion over 1 hr each HD; if undiluted, administer 125 mg IV at a rate of 12.5 mg/min
- Max: 125 mg/dose
Notes:- Minimum cumulative dose of 1 g of elemental iron x8 dialysis sessions may be required for achieving a favorable hemoglobin or hematocrit response in most patients
- Do not mix with other medications or add to parenteral nutrition solutions for IV infusion
Pediatric Dosing
Hemodialysis associated iron deficiency anemia
- >6 yrs
- 1.5 mg/kg of elemental iron diluted in 25 mL of 0.9% NaCl IV infusion over 1 hr during 8 sequential dialysis sessions
- Max: 125 mg/dose
Note:
- Do not mix with other medications or add to parenteral nutrition solutions for IV infusion
[Outline]
See Supplemental Patient Information
- Life-threatening and fatal hypersensitivity reactions, including anaphylactic-type reactions have been reported with injectable iron products in postmarketing experience
- Closely monitor patients for signs and symptoms of hypersensitivity during and after dose administration for at least 30 min and until clinically stable after completion of the infusion. Should be administered when facilities and therapies for treatment of anaphylaxis and hypersensitivity reactions are readily available
- Therapy may cause clinically significant hypotension. Hypotensive reactions including lightheadedness, fatigue, malaise, weakness or severe pain in the chest, back, flanks, or groin have been reported in patients receiving intravenous iron. These reactions may or may not be associated with hypersensitivity reactions and usually resolve within 1 to 2 hrs. Monitor patients for signs and symptoms of hypotension during and following administration of this product
- Excessive therapy may lead to excess iron storage with the possibility of iatrogenic hemosiderosis; monitor hematologic and iron parameters regularly during therapy
- Product contains benzyl alcohol as a preservative, which has been associated with serious adverse reactions and death in pediatric patients
Cautions: Use cautiously in
- Patients with iron overload
- Elderly patients
- Hemoglobinopathy
- Refractory anemia
Supplemental Patient Information
- Inform patients to report adverse reactions associated with parenteral iron use such as hypersensitivity, allergic reactions, lightheadedness, dizziness, swelling and breathing problems
- Advise patients that this product may reduce the absorption of concomitantly administered oral iron preparations
Pregnancy Category:B
Breastfeeding: Safety unknown. Manufacturer advises caution.
US Trade Name(s)
US Availability
sodium ferric gluconate complex (generic)
Ferrlecit
- INJ: 62.5 mg/5 mL (5 mL amp and vial)
Nulecit
Canadian Trade Name(s)
Canadian Availability
Ferrlecit
- INJ: 62.5 mg/5 mL (5 mL amp)
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability
[Outline]